vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and EXPRO GROUP HOLDINGS N.V. (XPRO). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $382.1M, roughly 1.9× EXPRO GROUP HOLDINGS N.V.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 1.5%, a 17.6% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -12.5%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $23.2M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs -0.2%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Expro is an energy services provider headquartered in Houston, Texas, United States.
MEDP vs XPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $382.1M |
| Net Profit | $135.1M | $5.8M |
| Gross Margin | — | — |
| Operating Margin | 21.6% | 3.1% |
| Net Margin | 19.1% | 1.5% |
| Revenue YoY | 32.0% | -12.5% |
| Net Profit YoY | 15.5% | -74.9% |
| EPS (diluted) | $4.65 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $382.1M | ||
| Q3 25 | $659.9M | $411.4M | ||
| Q2 25 | $603.3M | $422.7M | ||
| Q1 25 | $558.6M | $390.9M | ||
| Q4 24 | $536.6M | $436.8M | ||
| Q3 24 | $533.3M | $422.8M | ||
| Q2 24 | $528.1M | $469.6M | ||
| Q1 24 | $511.0M | $383.5M |
| Q4 25 | $135.1M | $5.8M | ||
| Q3 25 | $111.1M | $14.0M | ||
| Q2 25 | $90.3M | $18.0M | ||
| Q1 25 | $114.6M | $13.9M | ||
| Q4 24 | $117.0M | $23.0M | ||
| Q3 24 | $96.4M | $16.3M | ||
| Q2 24 | $88.4M | $15.3M | ||
| Q1 24 | $102.6M | $-2.7M |
| Q4 25 | 21.6% | 3.1% | ||
| Q3 25 | 21.5% | 6.4% | ||
| Q2 25 | 20.9% | 7.7% | ||
| Q1 25 | 20.3% | 2.6% | ||
| Q4 24 | 23.4% | 7.3% | ||
| Q3 24 | 21.1% | 6.2% | ||
| Q2 24 | 19.9% | 5.9% | ||
| Q1 24 | 20.4% | 2.2% |
| Q4 25 | 19.1% | 1.5% | ||
| Q3 25 | 16.8% | 3.4% | ||
| Q2 25 | 15.0% | 4.3% | ||
| Q1 25 | 20.5% | 3.6% | ||
| Q4 24 | 21.8% | 5.3% | ||
| Q3 24 | 18.1% | 3.8% | ||
| Q2 24 | 16.7% | 3.3% | ||
| Q1 24 | 20.1% | -0.7% |
| Q4 25 | $4.65 | $0.05 | ||
| Q3 25 | $3.86 | $0.12 | ||
| Q2 25 | $3.10 | $0.16 | ||
| Q1 25 | $3.67 | $0.12 | ||
| Q4 24 | $3.67 | $0.20 | ||
| Q3 24 | $3.01 | $0.14 | ||
| Q2 24 | $2.75 | $0.13 | ||
| Q1 24 | $3.20 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $196.1M |
| Total DebtLower is stronger | — | $79.1M |
| Stockholders' EquityBook value | $459.1M | $1.5B |
| Total Assets | $2.0B | $2.3B |
| Debt / EquityLower = less leverage | — | 0.05× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | $196.1M | ||
| Q3 25 | $285.4M | $197.9M | ||
| Q2 25 | $46.3M | $206.8M | ||
| Q1 25 | $441.4M | $179.3M | ||
| Q4 24 | $669.4M | $183.0M | ||
| Q3 24 | $656.9M | $165.7M | ||
| Q2 24 | $510.9M | $133.5M | ||
| Q1 24 | $407.0M | $163.2M |
| Q4 25 | — | $79.1M | ||
| Q3 25 | — | $99.1M | ||
| Q2 25 | — | $121.1M | ||
| Q1 25 | — | $121.1M | ||
| Q4 24 | — | $121.1M | ||
| Q3 24 | — | $121.1M | ||
| Q2 24 | — | $121.1M | ||
| Q1 24 | — | $40.0M |
| Q4 25 | $459.1M | $1.5B | ||
| Q3 25 | $293.6M | $1.5B | ||
| Q2 25 | $172.4M | $1.5B | ||
| Q1 25 | $593.6M | $1.5B | ||
| Q4 24 | $825.5M | $1.5B | ||
| Q3 24 | $881.4M | $1.5B | ||
| Q2 24 | $763.6M | $1.5B | ||
| Q1 24 | $671.5M | $1.3B |
| Q4 25 | $2.0B | $2.3B | ||
| Q3 25 | $1.8B | $2.3B | ||
| Q2 25 | $1.6B | $2.3B | ||
| Q1 25 | $1.9B | $2.3B | ||
| Q4 24 | $2.1B | $2.3B | ||
| Q3 24 | $2.1B | $2.3B | ||
| Q2 24 | $1.9B | $2.3B | ||
| Q1 24 | $1.8B | $2.0B |
| Q4 25 | — | 0.05× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.08× | ||
| Q1 25 | — | 0.08× | ||
| Q4 24 | — | 0.08× | ||
| Q3 24 | — | 0.08× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | — | 0.03× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $57.1M |
| Free Cash FlowOCF − Capex | $188.1M | $23.2M |
| FCF MarginFCF / Revenue | 26.6% | 6.1% |
| Capex IntensityCapex / Revenue | 0.6% | 8.9% |
| Cash ConversionOCF / Net Profit | 1.43× | 9.89× |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $97.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $57.1M | ||
| Q3 25 | $246.2M | $63.2M | ||
| Q2 25 | $148.5M | $48.4M | ||
| Q1 25 | $125.8M | $41.5M | ||
| Q4 24 | $190.7M | $97.4M | ||
| Q3 24 | $149.1M | $55.3M | ||
| Q2 24 | $116.4M | $-13.2M | ||
| Q1 24 | $152.7M | $29.9M |
| Q4 25 | $188.1M | $23.2M | ||
| Q3 25 | $235.5M | $39.0M | ||
| Q2 25 | $142.4M | $27.2M | ||
| Q1 25 | $115.8M | $8.4M | ||
| Q4 24 | $183.0M | $53.0M | ||
| Q3 24 | $138.5M | $23.3M | ||
| Q2 24 | $103.5M | $-49.5M | ||
| Q1 24 | $147.2M | $-801.0K |
| Q4 25 | 26.6% | 6.1% | ||
| Q3 25 | 35.7% | 9.5% | ||
| Q2 25 | 23.6% | 6.4% | ||
| Q1 25 | 20.7% | 2.1% | ||
| Q4 24 | 34.1% | 12.1% | ||
| Q3 24 | 26.0% | 5.5% | ||
| Q2 24 | 19.6% | -10.5% | ||
| Q1 24 | 28.8% | -0.2% |
| Q4 25 | 0.6% | 8.9% | ||
| Q3 25 | 1.6% | 5.9% | ||
| Q2 25 | 1.0% | 5.0% | ||
| Q1 25 | 1.8% | 8.5% | ||
| Q4 24 | 1.4% | 10.2% | ||
| Q3 24 | 2.0% | 7.6% | ||
| Q2 24 | 2.4% | 7.7% | ||
| Q1 24 | 1.1% | 8.0% |
| Q4 25 | 1.43× | 9.89× | ||
| Q3 25 | 2.22× | 4.52× | ||
| Q2 25 | 1.65× | 2.69× | ||
| Q1 25 | 1.10× | 2.98× | ||
| Q4 24 | 1.63× | 4.23× | ||
| Q3 24 | 1.55× | 3.40× | ||
| Q2 24 | 1.32× | -0.86× | ||
| Q1 24 | 1.49× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
XPRO
| NLA | $130.3M | 34% |
| ESSA | $116.3M | 30% |
| MENA | $93.0M | 24% |
| Other | $42.5M | 11% |
